Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — BARDA Industry Day (January 2011)
27 slides from Aethlon Medical's conference presentation, Jan 12, 2011
Slide 1: BARDA Industry Day Presentation
U.S. Department of Health and Human Services BARDA Industry Day Presentation Washington, DC January 12, 20100 James A. Joyce Chairman, CEO
Slide 2: Forward Looking Statements
Forward Looking Statements MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURI
Slide 3: A Broad-Spectrum Antiviral Platform Technology
A Broad-Spectrum Antiviral Platform Technology
Slide 4: The BARDA Strategic Objectives
The BARDA Strategic Objectives • To identify and support the development of innovative broad-spectrum: • Countermeasures • Technologies • Platforms • Strategies that address traditional, enhanced, emerging, and advanced threats • Adjunct or adjuvant therapies that improve countermeasure performance
Slide 5: The Hemopurifier
The Hemopurifier® The first medical device to selectively remove infectious viruses and immunosuppressive toxins from circulation
Slide 6: Leverages the established infrastructure of 90,000+ U.S. based dialysis stations
Leverages the established infrastructure of 90,000+ U.S. based dialysis stations
Slide 7: Additional Infrastructure to Deliver Hemopurifier Therapy
Additional Infrastructure to Deliver Hemopurifier® Therapy • CRRT machines already located in hospitals and clinics throughout the U.S. • Portable pump configurations
Slide 8: Mechanism of Action
Mechanism of Action Mannose 1. Separation of particles below 250nm from the circulatory system 2. Immobilized lectin affinity agents then selectively bind to unique high mannose structures resident on viral glycoproteins that coat viral pathogens
Slide 9: Lectin Binding Sites
Lectin Binding Sites
Slide 10: Dual Benefit of Action
Dual Benefit of Action Antiviral & Immunotherapeutic • Antiviral • Rapid real-time clearance of infectious viral pathogens • Immunotherapeutic • Fulfills unmet medical need of clearing virally-shed immunosuppressive glycoproteins
Slide 11: Hemopurifier Selected Quick Facts
• Regulatory Path: Device vs. Drug • 70 human treatment experiences • IDE on file with FDA • GMP manufacturing already established • Substantial viral load reductions in human HIV and HCV studies • Follow-on HCV studies initiated • Proven broad-spectrum capabilities against bioterror and pandemic th
Slide 12: In Vitro Confirmations Against Bioterror and Pandemic Threats
Virus Collaborator Ebola USAMRIID/CDC Dengue NIV/WHO Lassa SFBR West Nile Battelle H5N1 Avian Battelle 1918-r Spanish Flu Battelle 2009 H1N1 Swine Battelle Monkey Pox Battelle In Vitro Confirmations Against Bioterror and Pandemic Threats
Slide 13: Improves public health emergency preparedness
The Hemopurifier® improves public health emergency preparedness against: • Traditional Threats • Enhanced Agents • Emerging Pathogens • Advanced Agents
Slide 14: Ken Alibek quote on the Hemopurifier
"The Aethlon Hemopurifier® is the only strategy to address the breadth of pathogens that could be weaponized as agents of bioterrorism." Ken Alibek First Deputy Director of Biopreparat
Slide 15: Traditional Threats
Traditional Threats Known naturally occurring threats such as Smallpox, Ebola, Marburg, Lassa • The Hemopurifier® serves as an adjunct to improve the benefit of established and candidate treatment strategies • The Hemopurifier® provides a first-line countermeasure strategy against threats not addres
Slide 16: Enhanced Agents
Enhanced Agents Traditional threats that have been genetically modified to enhance virulence or circumvent drug and vaccine therapies • The Hemopurifier® serves as a first-line countermeasure against enhanced agents • Provides adjunct strategy to strengthen benefit of therapies proven safe and effec
Slide 17: Emerging Pathogens
Emerging Pathogens Previously unrecognized pathogens that occur naturally such as SARS or future strains of pandemic influenza • The Hemopurifier® is a candidate first-line countermeasure against emerging pathogens • Provides adjunct strategy to strengthen benefit of therapies proven safe and effect
Slide 18: Advanced Agents
Advanced Agents Novel pathogen artificially engineered to bypass traditional drug and vaccine countermeasures or enhance disease severity • The Hemopurifier® represents the sole first-line treatment strategy against advanced agents • Assists in early characterization of advanced agents
Slide 19: At-risk populations addressed by the Hemopurifier
The Hemopurifier® also provides a therapeutic mechanism to address at-risk populations for whom drug and vaccine therapies may be contraindicated • Immunocompromised • Children • Pregnant women • Senior Citizens
Slide 20: Stockpile Implications
Stockpile Implications • > 4 year shelf life • Refrigeration not required • Therapeutic demand in HCV, HIV, and cancer provides replenishing FIFO stockpile
Slide 21: Selected Examples of Therapeutic Filtration
Selected Examples of Therapeutic Filtration • Kidney dialysis • Hepatitis-C Virus • Marburg Plasmapheresis (1990) • Anthrax Toxin Plasmapheresis (2001)
Slide 22: 2001 Anthrax Survivor
2001 Anthrax Survivor "It's hard to say what saved me, but one of the things was plasmapheresis. Honestly, without it, I would be dead." Leroy Richmond Anthrax infected postal worker
Slide 23: An Adaptable Platform Technology
An Adaptable Platform Technology • The Hemopurifier® provides a platform for multi-use product development and manufacture • Interchanging affinity agents within our core Hemopurifier® cartridge expands targets beyond viral threats • Bacterial threats such as Anthrax could be addressed through immob
Slide 24: Conclusions
Conclusions • The Hemopurifier® fulfills BARDA's strategy objectives • It is an innovative broad-spectrum medical countermeasure • Offers a strategy to address traditional, enhanced, emerging, and advanced threats • Serves as an adjunct to enhance the benefit of drug and vaccine countermeasures
Slide 25: Conclusion
Conclusion The Aethlon Hemopurifier® represents the most advanced broad- spectrum countermeasure against bioterror and emerging pandemic threats
Slide 26: Aethlon Medical address and website
8910 University Center Lane, Suite 660 San Diego, CA. 92122 www.AethlonMedical.com
Slide 27: Presenter Information
Presenter Information Jim Joyce Chairman, CEO Aethlon Medical, Inc. (858) 459-7800 x301 jj@aethlonmedical.com